[go: up one dir, main page]

BR0116010A - Kit imunoterapêutico para o tratamento de tumores - Google Patents

Kit imunoterapêutico para o tratamento de tumores

Info

Publication number
BR0116010A
BR0116010A BR0116010-9A BR0116010A BR0116010A BR 0116010 A BR0116010 A BR 0116010A BR 0116010 A BR0116010 A BR 0116010A BR 0116010 A BR0116010 A BR 0116010A
Authority
BR
Brazil
Prior art keywords
tyrosine kinase
receptor
kinase activity
kit
tumors
Prior art date
Application number
BR0116010-9A
Other languages
English (en)
Inventor
Rolando Perez Rodriguez
Gisela Maria Gonzale Marinello
Tania Crombet Ramos
Irene Beausoleil Delgado
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of BR0116010A publication Critical patent/BR0116010A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001131—Epidermal growth factor [EGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001134—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"KIT IMUNOTERAPêUTICO PARA O TRATAMENTO DE TUMORES". A presente invenção relaciona-se com o campo da imunologia e, mais especificamente, com a imunoterapia do câncer, particularmente com um kit imunoterapêutico para impedir o crescimento de células de tumor e/ou eliminar referidas células. O kit da invenção é útil para o tratamento de tumores, que tem efeito sobre células cujo crescimento é dependente do sistema de receptores com atividadede tirosina quinase, caracterizado pelo fato de que compreende os componentes A, B, C e D que são usados simultaneamente ou seq³encialmente nas combinações de A+C; ou A+D; ou B+C; ou 8+D; ou C+D, em que A, B, C e D são:A. um anticorpo contra um receptor de atividade de tirosina quinase;B. um anticorpo contra o(s) ligando(s) do receptor de atividade de tirosina quinase; C.-uma vacina cujo princípio ativo é um receptor de atividade de tirosina quinase, que induz anticorpos contra referido receptor de atividade de tirosina quinase; D.-uma vacina cujo princípio é o(s) ligando(s) de um receptor de atividade de tirosina quinase, que induz anticorpos contra referidos ligando(s) do receptor de atividade de tirosina quinase. O kit proporciona o meio de realizar combinação terapêutica de imunoterapia passiva e ativa. Os procedimentos referenciados podem ser aplicados em diferentes estágios clinicos com tumores de origem epitelial que sobre-expressam esses receptores. A combinação de terapia passiva e ativa pode ser simultânea ou seq³encial independentemente de se o procedimento terapêutico vai ser usado em pacientes com doença avançada ou como terapia adjuvante.
BR0116010-9A 2000-12-08 2001-12-06 Kit imunoterapêutico para o tratamento de tumores BR0116010A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20000287A CU22979A1 (es) 2000-12-08 2000-12-08 Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
PCT/CU2001/000012 WO2002045747A1 (es) 2000-12-08 2001-12-06 Combinaciones inmunoterapeuticas para el tratamiento de tumores

Publications (1)

Publication Number Publication Date
BR0116010A true BR0116010A (pt) 2004-01-06

Family

ID=40261022

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116010-9A BR0116010A (pt) 2000-12-08 2001-12-06 Kit imunoterapêutico para o tratamento de tumores

Country Status (25)

Country Link
US (2) US20020160014A1 (pt)
EP (2) EP2005996A3 (pt)
JP (2) JP2005519023A (pt)
KR (1) KR20030064416A (pt)
CN (1) CN1326566C (pt)
AR (1) AR031641A1 (pt)
AT (1) ATE403438T1 (pt)
AU (2) AU2002221521B2 (pt)
BR (1) BR0116010A (pt)
CA (1) CA2431199C (pt)
CU (1) CU22979A1 (pt)
CY (1) CY1108474T1 (pt)
DE (1) DE60135248D1 (pt)
DK (1) DK1350521T3 (pt)
EA (1) EA007381B1 (pt)
ES (1) ES2311036T3 (pt)
MX (1) MXPA03005030A (pt)
MY (1) MY138833A (pt)
NZ (1) NZ526284A (pt)
PE (1) PE20020695A1 (pt)
PT (1) PT1350521E (pt)
SI (1) SI1350521T1 (pt)
UY (1) UY27058A1 (pt)
WO (1) WO2002045747A1 (pt)
ZA (1) ZA200304415B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
CA2665528C (en) * 2006-10-12 2018-01-23 The University Of Tokyo Diagnosis and treatment of cancer using anti-ereg antibody
CU23652A1 (es) * 2007-06-29 2011-05-27 Centro Inmunologia Molecular Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención
PE20091326A1 (es) 2008-01-17 2009-09-18 Irm Llc Anticuerpos anti-trkb mejorados
JP5808052B2 (ja) 2009-05-29 2015-11-10 中外製薬株式会社 Ｅｇｆファミリーリガンドのアンタゴニストを成分とする医薬組成物
WO2012018260A1 (en) * 2010-08-05 2012-02-09 Universiteit Utrecht Holding B.V. Epidermal growth factor receptor targeted immune therapy
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
CA3053239A1 (en) * 2017-02-17 2018-08-23 George Todaro Use of tgf alpha for the treatment of diseases and disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
JPH01221326A (ja) * 1988-02-29 1989-09-04 Toyo Jozo Co Ltd 悪性腫瘍細胞障害剤
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
ES2144440T3 (es) * 1992-08-18 2000-06-16 Centro Inmunologia Molecular Anticuerpos monoclonales que reconocen el receptor del factor de crecimiento epidermico, celulas y metodos para su produccion y compuestos que los contienen.
CA2137639C (en) * 1993-12-09 1999-01-26 Agustin B. L. Davila Vaccine composition comprising autologous epidermal growth factor or a fragment or a derivate thereof having anti-tumor activity and use thereof in the therapy of malignant diseases
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
NZ500748A (en) * 1997-05-12 2001-06-29 Aphton Corp Methods for the treatment of gastrin-dependent tumours comprising active or passive immunisation with an anti-CCK-B/gastrin receptor immunogen or anti-CCK-B/gastrin receptor antibodies
US20030219380A1 (en) * 1997-11-07 2003-11-27 Annie Fong Method of determining an efficacious dose of a drug
JP2002514573A (ja) * 1998-05-08 2002-05-21 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 能動的なワクチン接種のための組成物および方法
CA2332331A1 (en) * 1998-05-15 1999-11-25 Francisco Robert Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
JP2003532740A (ja) * 2000-05-05 2003-11-05 アフトン コーポレーション キメラペプチド免疫原
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas

Also Published As

Publication number Publication date
ATE403438T1 (de) 2008-08-15
NZ526284A (en) 2004-11-26
EP2005996A3 (en) 2012-01-25
WO2002045747A1 (es) 2002-06-13
EP2005996A2 (en) 2008-12-24
DK1350521T3 (da) 2008-11-10
AR031641A1 (es) 2003-09-24
US20060188497A1 (en) 2006-08-24
CN1326566C (zh) 2007-07-18
JP2010150286A (ja) 2010-07-08
AU2002221521B2 (en) 2007-01-04
AU2152102A (en) 2002-06-18
MXPA03005030A (es) 2004-09-10
ZA200304415B (en) 2004-07-07
EP1350521A1 (en) 2003-10-08
CN1592636A (zh) 2005-03-09
CA2431199A1 (en) 2002-06-13
JP2005519023A (ja) 2005-06-30
CY1108474T1 (el) 2014-04-09
US7744871B2 (en) 2010-06-29
HK1073244A1 (zh) 2005-09-30
MY138833A (en) 2009-07-31
PE20020695A1 (es) 2002-09-23
EA200300646A1 (ru) 2003-10-30
KR20030064416A (ko) 2003-07-31
SI1350521T1 (sl) 2008-12-31
EP1350521B1 (en) 2008-08-06
DE60135248D1 (de) 2008-09-18
PT1350521E (pt) 2008-11-14
CU22979A1 (es) 2004-09-09
ES2311036T3 (es) 2009-02-01
CA2431199C (en) 2011-10-04
US20020160014A1 (en) 2002-10-31
EA007381B1 (ru) 2006-10-27
UY27058A1 (es) 2002-03-22

Similar Documents

Publication Publication Date Title
BladÉ et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant
Damian et al. Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma
BR0116010A (pt) Kit imunoterapêutico para o tratamento de tumores
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
BR0317376A (pt) Anticorpo humanizado (h14.18) do anticorpo 14.18 do camundongo que se liga a gd2 e sua fusão com il-2
ES2177964T3 (es) Procedimiento de produccion de celulas t activadas marcadas especificas de tumores y su uso para el tratamiento de tumores.
CY1113044T1 (el) Παραλλαγματα αντιγονου αρχεγονων κυτταρων προστατη (psca) και υποαλληλουχιες εξ αυτων
Zhu et al. The therapeutic effects of baicalin on vitiligo mice
Fransson et al. Clinical and immunohistochemical evaluation of psoriatic plaques treated with topical 5‐aminolaevulinic acid photodynamic therapy
ES2177509T3 (es) Empleo de anticuerpos para la vacunacion contra el cancer.
ATE226447T1 (de) Anti-fas antikörper gegen rheumatische krankheiten
BR0306732A (pt) Tratamentos em combinação para doença alérgica compreendendo a administração de um anticorpo anti-ige e composto antialérgico
Su et al. Receptor desensitization and blockade of the suppressive effects of prostaglandin E2 and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes
Shi et al. Spontaneous cancers, but not many induced ones in animals, resemble semi-new organisms that possess a unique programmed cell death mode different from apoptosis, senescent death, necrosis and stress-induced cell death
BRPI0518619A2 (pt) mÉtodo de tratar cÂncer em um mamÍfero, combinaÇço farmacÊutica, uso de uma composiÇço ou combinaÇço farmacÊutica e composiÇço imunogÊnica
ATE492287T1 (de) Tumor-vakzine mit allogenen oder xenogenen tumorzellen
Kato et al. Bullous pemphigoid after allogeneic hematopoietic stem cell transplantation
ATE286914T1 (de) Verwendung von blockierenden anti-tsh-rezeptor- antikörpern bei der therapie von hyperthyreosen sowie monoklonale antikörper für eine solche verwendung
Gascón et al. Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: protocol amendments
TWI824617B (zh) 促進毛髮生長的方法
Zhang et al. Mitogen-activated protein kinase kinase kinase 8 (MAP3K8) mediates the LH-induced stimulation of progesterone synthesis in the porcine corpus luteum
Fallahi et al. Autoimmune thyroiditis
GB2314334A (en) Improved production of antibodies through the use of antigen antibody complexes
Kiselev et al. LB1166 Identification of an activated langerhans cell population and its role in cutaneous immunity
Oss-Ronen et al. LB1161 CASZ1 and ZNF750 act redundantly to preserve differentiation programs in the developing mouse epidermis

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: REF. A RPI NO 2161 DE 05/06/2012.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.